ARCUS BIOSCIENCES INC (RCUS)
Health Care · biotechnology · NYSE
A clinical-stage biopharmaceutical company focused on discovering and developing innovative, small-molecule and antibody-based oncology therapies through a robust pipeline and strategic collaborations.
What ARCUS BIOSCIENCES INC does
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing differentiated small-molecule and antibody-based therapies for the treatment of cancer. The company leverages its internal discovery platform to build a pipeline of product candidates designed to address significant unmet medical needs in oncology. It relies heavily on collaborative partnerships to advance the development and potential commercialization of its investigational products.
Themes: oncology, drug discovery, immunotherapy, clinical-stage biotech
Fundamentals
- Price$23.83 as of 2026-10-08 close
- Market cap$3.0B as of 2026-07-30 (share count; price 2026-10-08)
- 1-year return+58.3% 2025-10-08 close $15.05 → 2026-10-08 close $23.83
- P/En/a negative earnings
- Net margin-1069.7% FY2025, SEC XBRL
- ROE-55.9% FY2025, SEC XBRL
- Debt / equity0.22 as of 2026-09-02
- Revenue growth (YoY)-50.0% as of 2026-09-02
- Revenue CAGR (3y)-4.6% SEC XBRL
- Beta1.41 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How RCUS compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
RCUS is not currently in any published Top 10 list. Its scores are below.
Top 10 score
23.7 #1370 of 1,379 scored · #149 of 151 in Health Care
Trend 59th (over the past 12 months this stock beat the market by 43.4 percentage points) and financial health 37th (debt to equity 0.2, free cash flow margin -1466.7%); weakest is profitability (1st, operating margin -1169.7%, return on equity -55.9%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How ARCUS BIOSCIENCES INC looks technically
ARCUS BIOSCIENCES INC (RCUS) is trading 3.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 257 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-06-16, breaking below its recent trading range. It is 24.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.9% below its 200-day average, the long-term trend line — a long-term downtrend | -3.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $27.55 | $27.55 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $24.80 | $24.80 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 27.9. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 257 trading days ago — a "golden cross", a bullish long-term signal | 257 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 16.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 35.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($22.80 to $27.90) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 20.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $31.73 | $31.73 |
|---|---|---|
| From the 52-week high | it is 24.9% below its 52-week high (its highest price of the past year) | -24.9% |
| Above the 52-week low | it is 80.4% above its 52-week low (its lowest price of the past year) | +80.4% |
| Below the 52-week high | it is 24.9% below its highest point of the past year | 24.9% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-16, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-16, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $49.10 (set on 2021-11-22) | $49.10 |
| Given back of the 52-week move | over the past year its closes ranged ($13.35 to $31.57), and it has given back roughly a third of its rise from last year’s low — 42% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.73 to $20.31. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 42.5% |
| From the all-time high | it is 51.5% below its all-time high | -51.5% |
| Nearest price level | it is trading 0.8% below a resistance level at $24.03 — a price it turned at twice since 2025-12-31, most recently on 2026-04-29. Since 2024-10-08 it has 8 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.8% |
| All-time low | its lowest closing price on record is $6.30 (set on 2019-08-05) | $6.30 |
| Above the all-time low | it is 278.3% above its all-time low | +278.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 90% of it) | 10th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.25 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.25 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $23.52 and $26.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $23.52 – $25.06 – $26.60 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges below its 200-day average price (3.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.00× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.0% since the prior reading | +3.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.12 toward buy |
Candlestick patterns
1
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.9% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-09-30 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 19.0 percentage points (the stock lost 18.0% while the market gained 1.0%) | -19.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 25.1 percentage points (the stock lost 21.2% while the market gained 3.8%) | -25.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 10.3 percentage points (the stock gained 7.1% while the market gained 17.5%) | -10.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 43.4 percentage points (the stock gained 58.3% while the market gained 15.0%) | +43.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.8% of the share price. | -14.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $25.18 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -5.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $27.01 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -11.8% |
Price levels it has turned at before
RCUS last closed at $23.83 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.03 | Resistance | 0.8% above the last close | turned there twice · 2025-12-31 to 2026-04-29 |
| $23.38 | Support | 1.9% below the last close | turned there twice · 2026-04-02 to 2026-09-15 |
| $24.82 | Resistance | 4.2% above the last close | turned there twice · 2026-03-02 to 2026-03-11 |
| $22.04 | Support | 7.5% below the last close | turned there twice · 2025-10-29 to 2026-06-11 |
| $26.17 | Resistance | 9.8% above the last close | turned there twice · 2026-06-01 to 2026-07-29 |
| $20.20 | Support | 15.2% below the last close | turned there three times · 2025-12-12 to 2026-04-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $27.90.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $22.47 and $25.83 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 7 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.31 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$39.91 range $23.00 – $47.00; median $43.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RCUS
- Consensus EPS estimate-$0.8643 next reporting period, as of 2026-10-05
- Estimate change, 30 days+$0.01714 from -$0.8814, on 2026-08-30, 36-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and no commercial revenue, with a significant need for additional capital.","High dependency on third-party collaborations and clinical trial partners for development success.","Regulatory, safety, and enrollment risks associated with the clinical development of oncology investigational products."]
What changed in the latest 10-Q
AI-assisted comparison of RCUS's 10-Q filed 2026-05-05 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references audited Consolidated Financial Statements for year ended December 31, 2025, filed February 25, 2026 (vs. older filing referencing year ended December 31, 2024, filed February 25, 2025)
- Addition of 'Significant Developments' subsection titled 'Corporate Developments' stating Gilead's option period will end July 14, 2026, after Gilead declined option continuation payment
- Addition stating Gilead will lose option rights to CCR6, CD89, and CD40L programs but maintain time-limited options to AB801, AB598, AB102, and TNF small molecule inhibitor
- Addition of 'Significant Developments' subsection stating AstraZeneca and Arcus agreed not to re-open enrollment in eVOLVE-RCC02 in March 2026
- Addition of 'Significant Developments' subsection stating Phase 3 STAR-121 study was discontinued in April 2026 due to futility
- Change in company description from 'clinical-stage biopharmaceutical company' to 'late clinical-stage biopharmaceutical company'
- Addition of statement that most advanced molecules are in Phase 3 registrational studies for various cancer indications
- Addition stating company expects next wave of clinical-stage molecules from inflammation and autoimmune disease programs
- Removed:
- Removal of detailed description of seven clinical programs and specific target details (HIF-2α, TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, AXL)
- Removal of detailed description of 2020 Gilead Collaboration Agreement background and structure
- Removal of statement that Gilead returned adenosine receptor antagonist program license in Q2 2025
- Removal of statement that HIF-2α program is no longer subject to Gilead's option
- Removal of extensive October 2025 HIF-2α casdatifan data presentation details (ARC-20 study results with specific mPFS, PFS landmarks, and cORR figures)
- Removal of October 2025 eVOLVE-RCC02 study pause announcement with details about Phase 1b recruitment, immune-mediated adverse events, and safety characterization plans
- Removal of reference to October 2025 EDGE-Gastric Phase 2 study overall survival results from Arm A1
- Removal of October 2025 Taiho option exercise announcement for casdatifan with milestone and royalty details
- Removal of clinical pipeline chart with detailed program abbreviations and combination therapy specifications
- Reworded:
- Header changed from 'Forward Looking Statements and Website Information' to 'Forward-Looking Statements and Website Information' (hyphenation added)
- Overview description changed from mentioning 'most advanced molecule, an anti-TIGIT antibody, now in multiple Phase 3 registrational studies' to focusing on HIF-2α program and stating molecules are in Phase 3 registrational studies for various cancer indications
- Removed specific mention of targeting lung and GI cancers; now uses broader language 'various cancer indications'
- Changed from describing 'deep portfolio of novel small molecules and enabling antibodies' to 'differentiated molecules'
- Removed emphasis on 'IO, cancer cell-intrinsic and immunological pathways' language from portfolio expansion description
- Notes:
- The newer filing text appears truncated at the end of the R&D expenses section and may be incomplete
- The older filing text also appears truncated at the end of the TIGIT Program section and may be incomplete
- Comparison limited to the portions of MD&A that are fully readable in both documents
Risk Factors
- Added:
- Risk factor: 'Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with Hercules Capital, Inc. ("Hercules"), as amended, and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.' (filed 2026-05-05)
- Risk factor: 'Preliminary, topline and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.' (filed 2026-05-05)
- Risk factor: 'Certain of our investigational products may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products.' (filed 2026-05-05)
- Risk factor: 'Any investigational products for which we intend to seek approval as biologic products may face competition sooner than anticipated.' (filed 2026-05-05)
- Risk factor: 'Risks Related to our In-Licenses and Other Strategic Agreements' section with related risk factors about breaching in-license agreements. (filed 2026-05-05)
- Risk factor: 'We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce, and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.' (filed 2026-05-05)
- Risk factor: 'Our internal information technology systems, and those of our third-party contract research organizations ("CROs") and other third parties upon which we rely, are subject to failure, security breaches and other disruptions, which could result in a material disruption of our investigational products' development programs, jeopardize sensitive information, prevent us from accessing critical information or result in a loss of our assets, and potentially expose us to notification obligations, loss, liability or reputational damage and otherwise adversely affect our business.' (filed 2026-05-05)
- Risk factor: 'Failure to comply with data privacy and data protection laws, regulations or other obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.' (filed 2026-05-05)
- Removed:
- Introductory language: 'You should consider carefully the following risk factors, together with all the other information in this report, including our Condensed Consolidated Financial Statements and notes thereto, and in our other public filings with the SEC. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.' (filed 2025-10-28)
- Detailed discussion of company's clinical-stage status, accumulated deficit of $1.4 billion, and specific net losses for nine months ended September 30, 2025 ($247 million) and year ended December 31, 2024 ($283 million). (filed 2025-10-28)
- Discussion of cash position of $841 million as of September 30, 2025 and funding sufficiency for initial pivotal read-outs of specific programs. (filed 2025-10-28)
- Example of paused development: 'etrumadenant in third-line metastatic colorectal cancer.' (filed 2025-10-28)
- Detailed discussion of capital requirements factors including 'the number, scope, rate of progress and costs of clinical programs,' 'the scope of any cost sharing arrangements with our strategic partners,' and 'the timing and amount of milestone payments and option fees we receive under the Gilead Collaboration Agreement and the Taiho Agreement.' (filed 2025-10-28)
- Detailed technical discussion of FDA regulatory approval process including 'submission of extensive preclinical and clinical data,' manufacturing process information, and facility inspection requirements. (filed 2025-10-28)
- Reworded:
- Formatting change: Newer filing presents risk factors as bullet points with shorter summaries; older filing included longer narrative paragraphs with detailed explanations and context. (filed 2026-05-05 vs 2025-10-28)
- Risk factor on operating losses: Newer version is condensed bullet point; older version included substantial narrative context about being clinical-stage company, accumulated deficit, and specific loss amounts. (filed 2026-05-05 vs 2025-10-28)
- Risk factor on funding: Newer version is condensed bullet point; older version included detailed discussion of capital intensity, specific cash position, funding sufficiency analysis, and enumerated capital requirement factors. (filed 2026-05-05 vs 2025-10-28)
- Risk factor on regulatory approval: Newer version is condensed bullet point; older version included detailed explanation of FDA and EMA processes, manufacturing requirements, and efficacy/safety considerations. (filed 2026-05-05 vs 2025-10-28)
- Notes:
- The newer filing appears to be a condensed summary format of risk factors, while the older filing contains more detailed narrative explanations. The comparison reflects the structural difference in how risk factors are presented rather than necessarily indicating substantive changes to disclosed risks.
- The text of the newer filing is truncated at the end (ending mid-sentence in financial statements section), so full completeness of the newer risk factors section cannot be fully verified.
- Both filings reference related party agreements (Gilead, Taiho) but the newer condensed format does not include the same level of specific reference detail.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($84810) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 10 sells ($3M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RCUS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding RCUS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 32,820,004
- Reported value $1,011,840,737
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about RCUS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
RCUS had 13,812,606 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
RCUS had 10.8% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.81 days to cover at the same settlement.
- Reported short interest (shares) 13,812,606
- Short interest (% of shares outstanding) 10.8%
- Prior settlement (shares) 13,076,244
- Reported change 5.63%
- Days to cover (reported) 7.81
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- Roche (RHHBY)
- AstraZeneca (AZN)
- Gilead Sciences (GILD)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RCUS vs…
ARCUS BIOSCIENCES INC is found in…
Frequently asked questions
What does ARCUS BIOSCIENCES INC (RCUS) do?
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing differentiated small-molecule and antibody-based therapies for the treatment of cancer. The company leverages its internal discovery platform to build a pipeline of product candidates designed to address significant unmet medical needs in oncology. It relies heavily on collaborative partnerships to advance the development and potential commercialization of its investigational products.
What sector is ARCUS BIOSCIENCES INC (RCUS) in?
ARCUS BIOSCIENCES INC (RCUS) is classified in the Health Care sector. Its industry is biotechnology. It trades on NYSE.
Who are ARCUS BIOSCIENCES INC's (RCUS) competitors?
Notable peers of ARCUS BIOSCIENCES INC (RCUS) include Merck, Bristol Myers Squibb, Roche, AstraZeneca and Gilead Sciences. This peer set is informational only — not financial advice.
Is ARCUS BIOSCIENCES INC (RCUS) overbought or oversold right now?
ARCUS BIOSCIENCES INC (RCUS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RCUS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.